Kanishk Kumar: Discovering The Newest Advances in Hypercholesterolemia Research

Kanishk Kumar, Digital Marketing Executive at Delvelnsight Business Research LLP, shared a post on LinkedIn:

“DelveInsight’s ‘Hypercholesterolemia Pipeline Insight, 2026’ report delivers an in-depth analysis of over 25 companies and more than 30 pipeline candidates within the Hypercholesterolemia therapeutic landscape. The report encompasses detailed drug profiles spanning both clinical and preclinical development stages. Additionally, it presents a thorough therapeutic evaluation categorized by product type, development phase, route of administration, and molecular classification, while also identifying inactive pipeline assets.

Discover the newest advances in Hypercholesterolemia research. Explore our cutting-edge pipeline today!

Major Highlights from the Hypercholesterolemia Pipeline Report

• In October , Novartis announced a randomized, double-blind, placebo- and active comparator-controlled, multicenter trial involving 350 adult subjects with primary hypercholesterolemia who were not on any lipid-lowering therapy (LLT) and had a 10-year ASCVD risk score below 7.5%. The trial assessed the efficacy and safety of inclisiran sodium 300 mg as monotherapy compared with ezetimibe and placebo.
• In October, Merck Group initiated a study aimed at evaluating the extended safety profile and therapeutic effectiveness of enlicitide decanoate in adults with hypercholesterolemia who had previously completed study MK-0616-013 (NCT05952856), study MK-0616-017 (NCT05952869), or study MK-0616-018 (NCT06450366
•  DelveInsight’s Hypercholesterolemia pipeline analysis reveals a dynamic landscape with 25+ active companies engaged in developing 30+ therapeutic candidates for Hypercholesterolemia management.
• Key Companies in Hypercholesterolemia Development include Merck Group , Arrowhead Pharmaceuticals , Vaxxinity, Akeso Biopharma , Haisco Pharmaceutical Group Co., Ltd , Verve Therapeutics , Amytrx Therapeutics Inc. , EPIC BIO, Addpharma, NewAmsterdam Pharma Corporation, LIB Therapeutics, and others.
• Notable Pipeline Candidates include Gemcabene, Rosuvastatin calcium, KJX839, statins, ezetimibe, MK-0524A, ER Niacin, and additional promising therapies.

Keep up with the latest breakthroughs in Hypercholesterolemia therapeutics. Download the report for the most recent updates and join the transformation in Cardiovascular Disease Management

The Hypercholesterolemia Pipeline Report offers a thorough disease overview, an assessment of the current pipeline landscape, and a therapeutic evaluation of key investigational drugs. It also identifies critical unmet medical needs associated with Hypercholesterolemia.

Understanding Hypercholesterolemia

Hypercholesterolemia represents a distinct form of hyperlipidemia characterized by elevated LDL-cholesterol levels—specifically, LDL-cholesterol exceeding 190 mg/dL, above 160 mg/dL in the presence of one significant risk factor, or surpassing 130 mg/dL when two or more cardiovascular risk factors are present. Although the condition can have a hereditary component, it frequently arises from unhealthy lifestyle habits, making it both preventable and manageable.

Adopting a balanced diet, engaging in regular physical activity, and utilizing medication when necessary can effectively lower cholesterol levels. Untreated hypercholesterolemia significantly elevates the risk of cardiovascular disease.

Profiles of Emerging Hypercholesterolemia Drug Candidates

MK-0616 – Merck Sharp and Dohme LLC

MK-0616 is an investigational compound poised to become the first oral PCSK9 inhibitor aimed at reducing low-density lipoprotein (LDL) cholesterol. Discovered and developed by Merck, this macrocyclic peptide functions by binding to PCSK9 and blocking its interaction with LDL receptors. MK-0616 is being advanced through a collaborative agreement with UCB Pharmaceuticals.

Data from the Phase IIb clinical trial demonstrated that MK-0616 was generally well-tolerated, with no notable trends in discontinuation rates or adverse events across treatment groups at the 16-week mark. No treatment-related serious adverse events were reported by investigators. The compound is currently in Phase III development for Hypercholesterolemia.

ARO-ANG3 – Arrowhead Pharmaceuticals

ARO-ANG3 is an investigational RNA interference (RNAi) therapeutic engineered to suppress the expression of angiopoietin-like protein 3 (ANGPTL3)—a liver-derived protein that regulates lipid and lipoprotein metabolism through multiple pathways, including inhibition of lipoprotein lipase and endothelial lipase. By reducing ANGPTL3 expression and circulating levels, ARO-ANG3 has the potential to enhance the clearance of LDL-cholesterol, HDL-cholesterol, and triglycerides. The drug is presently in Phase II clinical development for the treatment of Hypercholesterolemia.

VXX-401 – Vaxxinity, Inc.

VXX-401 was engineered using Vaxxinity’s proprietary synthetic peptide vaccine platform and is under development for hypercholesterolemia management. This innovative platform leverages the body’s immune system, effectively converting it into a natural “drug-producing factory” by stimulating targeted antibody production. VXX-401 is specifically designed to generate potent, long-lasting antibodies against PCSK9, thereby reducing LDL cholesterol levels to help prevent or treat coronary heart disease. The candidate is currently undergoing Phase I evaluation for Hypercholesterolemia.

Explore emerging opportunities in Hypercholesterolemia drug development through our pioneering research initiatives

What the Hypercholesterolemia Pipeline Report Covers

• Company-Level Analysis: Comprehensive profiles of organizations actively developing Hypercholesterolemia therapies, including an aggregated view of their respective therapeutic portfolios.
• Stage-Based Segmentation: Assessment of pipeline candidates categorized into early-stage, mid-stage, and late-stage development phases for Hypercholesterolemia treatment.
• Active and Inactive Projects: Overview of companies engaged in targeted therapeutic development, along with identification of dormant or discontinued initiatives.
• Drug Classification: Pipeline drugs organized by development stage, administration route, target receptor, treatment approach (monotherapy vs. combination therapy), mechanism of action, and molecular type.
• Strategic Analysis: Detailed examination of company-to-company and company-to-academia collaborations, licensing arrangements, and financial transactions shaping the future of the Hypercholesterolemia market.

Key Companies in Hypercholesterolemia Pipeline

Merck Group , Arrowhead Pharmaceuticals , Vaxxinity ., Akeso Biopharma , Haisco Pharmaceutical Group Co., Ltd , Verve Therapeutics , Amytrx Therapeutics, Inc. , EPIC BIO, Addpharma, NewAmsterdam Pharma Corporation ,LIB Therapeutics, and others.

Route of Administration

Pipeline products are classified across multiple administration routes, including:

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Molecule Type

Pipeline candidates are further categorized by molecular classification:

• Monoclonal Antibody
• Small Molecule
• Peptide

Explore the most recent innovations in Hypercholesterolemia therapy by visiting our platform. Stay updated on how we are reshaping the future of Cardiovascular Disease treatment

Report Scope

Geographic Coverage: Global

Key Companies: Merck Group , Arrowhead Pharmaceuticals , Vaxxinity ., Akeso Biopharma , Haisco Pharmaceutical Group Co., Ltd , Verve Therapeutics , Amytrx Therapeutics, Inc. , EPIC BIO, Addpharma, NewAmsterdam Pharma Corporation ,LIB Therapeutics, and others.

Key Pipeline Therapies: Gemcabene, Rosuvastatin calcium, KJX839, statins, ezetimibe, MK-0524A, ER Niacin, and additional candidates.

Therapeutic Assessment by Product Type: Monotherapy, Combination Therapy, Mono/Combination
• Therapeutic Assessment by Clinical Stage: Discovery, Preclinical, Phase I, Phase II, Phase III

For a comprehensive review of our findings and strategic outlook, access the complete Hypercholesterolemia Pipeline report

Table of Contents

1. Introduction
2. Executive Summary
3. Hypercholesterolemia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Hypercholesterolemia– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. MK-0616: Merck Sharp & Dohme LLC
9. Mid Stage Products (Phase II)
10. ARO-ANG 3: Arrowhead Pharmaceuticals
11. Early Stage Products (Phase I)
12. VXX-401: Vaxxinity, Inc.
13. Preclinical and Discovery Stage Products
14. Drug Name: Company Name
15. Inactive Products
16. Hypercholesterolemia Key Companies
17. Hypercholesterolemia Key Products
18. Hypercholesterolemia- Unmet Needs
19. Hypercholesterolemia- Market Drivers and Barriers
20. Hypercholesterolemia- Future Perspectives and Conclusion
21. Hypercholesterolemia Analyst Views
22. Hypercholesterolemia Key Companies
23. Appendix

About DelveInsight

DelveInsight is a premier healthcare-focused market research and consulting organization that equips clients with superior market intelligence and analytical capabilities to support well-informed business decisions. Backed by a team of seasoned industry professionals and extensive expertise in the life sciences and healthcare domains, the firm delivers tailored research solutions and actionable insights to clients worldwide. Partner with us to access high-quality, precise, and real-time intelligence that keeps you ahead of the competitive curve.

Contact Us

Kanishk”

Stay updated with Hemostasis Today.